Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation

To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ejaculation

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Pfizer Investigational Site, Tucson, Arizona, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Premature ejaculation as defined by DSM-IV

Exclusion criteria

History of erectile dysfunction

Treatment and study plan

UK-390,957

Drug

Primary outcomes

Assessment of efficacy and safety

Secondary outcomes

Assessment of Quality of Sexual Life

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2005
First posted: Sep 2, 2005
Registry last updated: Nov 7, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed